[
    [
        {
            "time": "",
            "original_text": "华东医药3.7亿元入股荃信生物 目标公司拥有8个在研药品",
            "features": {
                "keywords": [
                    "华东医药",
                    "荃信生物",
                    "股权融资",
                    "在研药品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药3.7亿元入股荃信生物 目标公司拥有8个在研药品",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药携手荃信生物 深度布局自免单抗管线",
            "features": {
                "keywords": [
                    "华东医药",
                    "荃信生物",
                    "战略合作",
                    "自免单抗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "免疫治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药携手荃信生物 深度布局自免单抗管线",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "华东医药(000963.SZ)：中美华东拟3.7亿元对荃信生物进行股权投资 双方已签订产品合作开发协议",
            "features": {
                "keywords": [
                    "华东医药",
                    "中美华东",
                    "荃信生物",
                    "股权投资",
                    "产品开发协议"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药(000963.SZ)：中美华东拟3.7亿元对荃信生物进行股权投资 双方已签订产品合作开发协议",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "华东医药：子公司中美华东与荃信生物达成股权投资和产品合作开发协议",
            "features": {
                "keywords": [
                    "华东医药",
                    "中美华东",
                    "荃信生物",
                    "股权投资",
                    "产品开发"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：子公司中美华东与荃信生物达成股权投资和产品合作开发协议",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华东医药：拟对荃信生物进行股权投资将成为其第二大股东",
            "features": {
                "keywords": [
                    "华东医药",
                    "荃信生物",
                    "股权投资",
                    "第二大股东"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "华东医药：拟对荃信生物进行股权投资将成为其第二大股东",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "苑东生物多项财务数据异常，“穿越时空”与供应商合作 欺诈造假",
            "features": {
                "keywords": [
                    "苑东生物",
                    "财务数据异常",
                    "欺诈造假",
                    "供应商合作"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "苑东生物多项财务数据异常，“穿越时空”与供应商合作 欺诈造假",
                "Correlation": 2,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]